46 results on '"Child, Christopher J."'
Search Results
2. Development of a Measure to Assess Attitudes Towards Nasal versus Autoinjector Glucagon Delivery Devices for Treatment of Severe Hypoglycemia
Catalog
Books, media, physical & digital resources
3. Conversations and Reactions Around Severe Hypoglycemia (CRASH) Study: Results From People With Diabetes and Caregivers in the United States
4. Conversations and Reactions Around Severe Hypoglycemia (CRASH) Study: Results From People With Diabetes and Caregivers in the United States
5. Conversations and Reactions Around Severe Hypoglycemia (CRASH) Study: Results From People With Diabetes and Caregivers in the United States
6. Nasal Glucagon Is Easier to Use and More Preferred and Needs Less Effort to Administer Than Injectable Glucagon: User Perceptions of Glucagon Administration During Severe Hypoglycemia Simulation
7. Indirect treatment comparison of ready-to-use glucagon rescue treatments for severe hypoglycemia: Nasal glucagon versus liquid stable glucagon
8. Potential Risk Factors for Severe Hypoglycemia in Insulin-treated Adults with Type 2 Diabetes (T2D)
9. Nasal Glucagon was Efficacious in Reversing Insulin-Induced Hypoglycemia Across a Range of Nadir Blood Glucose Levels
10. Previously unrecognized risk factors for severe hypoglycaemia requiring emergency medical care in insulin‐treated type 2 diabetes: Results from a real‐world nested case‐control study
11. 348-P: Nasal Glucagon Was Efficacious in Reversing Insulin-Induced Hypoglycemia across a Range of Nadir Blood Glucose Levels
12. 1039-P: Potential Risk Factors for Severe Hypoglycemia in Insulin-Treated Adults with Type 2 Diabetes (T2DM)
13. 138-OR: Indirect Treatment Comparison of Ready-to-Use Glucagon Rescue Treatments for Severe Hypoglycemia: Nasal Glucagon vs. Liquid Stable Glucagon
14. Short Stature Homeobox-Containing (SHOX) Gene Deficiency: Genetics and Growth Response to Growth Hormone Treatment in Comparison with Turner Syndrome
15. Assessment of Primary Cancers in Growth Hormone-Treated Adult Hypopituitary Patients Compared to Population Databases: An Analysis of the Hypopituitary Control and Complications Study (HypoCCS)
16. 129-LB: Evaluation of Attitudes towards Two Glucagon Delivery Devices for Rescue Treatment of Severe Hypoglycemia
17. 1085-P: Nasal Glucagon Was Efficacious in Reversing Insulin-Induced Hypoglycemia without Increasing Risk of Secondary Hyperglycemia
18. 268-OR: Conversations and Reactions around Severe Hypoglycemia (CRASH): Survey Responses of People Aged 65+ with T1DM or Insulin-Treated T2DM and Caregivers
19. 1074-P: Nasal Glucagon Reversed Insulin-Induced Hypoglycemia in Adults with Diabetes: A Pooled Analysis
20. Nasal Glucagon Delivery is More Successful than Injectable Delivery: A Simulated Severe Hypoglycemia Rescue
21. Perceptions About Glucagon Delivery Devices for Severe Hypoglycemia: Qualitative Research With Patients, Caregivers, and Acquaintances
22. 285-OR: Conversations and Reactions around Severe Hypoglycemia (CRASH): U.S. Results from a Global Survey of People with T1DM or Insulin-Treated T2DM and Caregivers
23. 13-LB: Nasal vs. Injected Glucagon: User Experience Results of a Simulated Severe Hypoglycemia Study
24. Height Gain and Safety Outcomes in Growth Hormone-Treated Children with Idiopathic Short Stature: Experience from a Prospective Observational Study
25. Screening a large pediatric cohort with GH deficiency for mutations in genes regulating pituitary development and GH secretion: Frequencies, phenotypes and growth outcomes
26. Safety Outcomes During Pediatric GH Therapy: Final Results From the Prospective GeNeSIS Observational Program
27. Growth hormone treatment of Canadian children: results from the GeNeSIS phase IV prospective observational study
28. Responses to the Letter to the Editor “Does growth-hormone treatment affect patients with and without a mitochondrial disorder differentially ?” (Vol. 27, No. 2, p. 107–108, 2018)
29. Growth Hormone Treatment for Short Stature in the USA, Germany and France: 15 Years of Surveillance in the Genetics and Neuroendocrinology of Short-Stature International Study (GeNeSIS)
30. Mortality in Children Receiving Growth Hormone Treatment of Growth Disorders: Data From the Genetics and Neuroendocrinology of Short Stature International Study
31. Incidence of diabetes mellitus and neoplasia in Japanese short-statured children treated with growth hormone in the Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS)
32. Safety Outcomes and Near-Adult Height Gain of Growth Hormone-Treated Children with SHOX Deficiency: Data from an Observational Study and a Clinical Trial
33. Development of additional pituitary hormone deficiencies in pediatric patients originally diagnosed with isolated growth hormone deficiency due to organic causes
34. Assessment of Primary Cancer Incidence in Growth Hormone-Treated Children: Comparison of a Multinational Prospective Observational Study with Population Databases
35. Incidence of primary cancers and intracranial tumour recurrences in GH-treated and untreated adult hypopituitary patients: analyses from the Hypopituitary Control and Complications Study
36. Radiological Features in Patients with Short Stature Homeobox-Containing (SHOX) Gene Deficiency and Turner Syndrome before and after 2 Years of GH Treatment
37. Development of additional pituitary hormone deficiencies in pediatric patients originally diagnosed with idiopathic isolated GH deficiency
38. GH Treatment to Final Height Produces Similar Height Gains in Patients With SHOX Deficiency and Turner Syndrome: Results of a Multicenter Trial
39. Incidence of second neoplasm in childhood cancer survivors treated with GH: an analysis of GeNeSIS and HypoCCS
40. Associations between Pituitary Imaging Abnormalities and Clinical and Biochemical Phenotypes in Children with Congenital Growth Hormone Deficiency: Data from an International Observational Study
41. Assessment of primary cancers in GH-treated adult hypopituitary patients: an analysis from the Hypopituitary Control and Complications Study
42. Prevalence and Incidence of Diabetes Mellitus in GH-Treated Children and Adolescents: Analysis from the GeNeSIS Observational Research Program
43. Mutations and Pituitary Morphology in a Series of 82 Patients with PROP1 Gene Defects
44. Continued Growth Hormone (GH) Treatment after Final Height Is Necessary to Complete Somatic Development in Childhood-Onset GH-Deficient Patients
45. Effect of Growth Hormone (GH) Treatment on Bone in Postpubertal GH-Deficient Patients: A 2-Year Randomized, Controlled, Dose-Ranging Study
46. Structural Similarities between 6-Methylsalicylic Acid Synthase from Penicillium patulum and Vertebrate Type I Fatty Acid Synthase: Evidence from Thiol Modification Studies
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.